Table 3. Published literature of the use of cranial radiation boost in ALL prior to alloHCT.

Study reference	Transplant type	Treatment groups	All Relapse	Post-transplant CNS relapse	OS	DFS	Conclusion
Gao RW et al 2016(n-213)	MRD/MUD/CBT CR1	Total relapse CNS−/CRB−(n-160) CNS+/CRB+(n-11/30) CNS+/CRB-(n-11) CNS + PriorRT (n-12)	N-63 43/160; 26.9% 2/30; 6.7% 5/11; 45.5% 3/12; 25.0%	7(1.7%) n-4(2.5% n-2(6.6% n- 1(9%) N-Zero	2-yr OS 60% (95%CI: 53%- 67%) P-0.81	2-yr 54% (95% CI, 47%-61%)	No benefit of CRB in patients with no CNS disease, Benefit in patients with history of CNS involvement
Sue William et al 2016(n-55)	Allo-HCT-CR1 High risk	CRB group (n-36) No CRB group (n-19)	n-13 10 n-3	n-3 n-1 n-2	3-yr CNS free OS 63% 3-yr CNS free OS 82%	3-yr CNS free DFS 95% 3-yr CNS free DFS 52% 7-yr CNS RFS (100% vs 76.4% P-0.043)	Benefit of CRB in CNS -/CRB+.
Famoso Justin M et al 2019(n-58)	Allo-HCT High risk	CRB group No CRB group			7-yr OS 49.4% vs 43.5%; P = 0.921	7-yr PFS 78.3% vs 62.5%; P = 0.076) 7-year CNS RFS (100% vs 76.4% P = 0.043)	Benefit of CRB in CNS -/CRB+. high risk patients